metastatic/adv melanoma (mML) | |
mML - L1 - all population | |
nivolumab followed by ipilimumab | CheckMate 064 |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-